Previous Close | 0.0000 |
Open | 0.0000 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 0.0000 - 0.0000 |
52 Week Range | 0.0000 - 0.4582 |
Volume | |
Avg. Volume | 1,015 |
Market Cap | 11 |
Beta (5Y Monthly) | 0.98 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.5500 |
Earnings Date | Mar 14, 2024 - Mar 18, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.00 |
DARTMOUTH, Nova Scotia, September 01, 2023--IMV Inc. (the "Company" or "IMV") announces today that it has accepted an offer (the "Offer") from IMV’s largest secured creditors (the "Secured Lenders"), pursuant to which IMV and its subsidiary, Immunovaccine Technologies Inc. have agreed to sell to the Secured Lenders its intellectual property assets (the "Transaction") in consideration for a partial reduction of debt owing to the Secured Lenders.
DARTMOUTH, Nova Scotia, July 26, 2023--IMV Inc. (the "Company" or "IMV"), recently announced an update on the Sales and Investment Solicitation Process (the "SISP") implemented as part of its ongoing proceedings under the Companies' Creditors Arrangement Act (the "CCAA").